Clinical Trials Logo

Biliary Tract Cancer clinical trials

View clinical trials related to Biliary Tract Cancer.

Filter by:
  • Not yet recruiting  
  • « Prev · Page 2

NCT ID: NCT05417230 Not yet recruiting - Clinical trials for Biliary Tract Cancer

RC48-ADC Combinatioed Envolizumab in Locally Advanced or Metastatic Biliary Tract Cancer With Positive HER-2

Start date: August 2022
Phase: Phase 2
Study type: Interventional

This study was a prospective, single-arm phase II clinical trial to observe and evaluate the efficacy and safety of RC48-ADC combined envafolimab in the first-line treatment of locally advanced or metastatic biliary tract cancer with positive HER-2.

NCT ID: NCT04571710 Not yet recruiting - Clinical trials for Biliary Tract Cancer

A Trial of SHR1258 in Patients With Biliary Tract Cancer

Start date: November 1, 2020
Phase: Phase 2
Study type: Interventional

The study is being conducted to evaluate the efficacy and safety of SHR1258 in subjects with advanced/ metastatic HER2-altered biliary tract cancers

NCT ID: NCT03760289 Not yet recruiting - Clinical trials for Biliary Tract Cancer

DKN-01/Atezolizumab as Second Line Treatment of biliarY Tract Cancer and in combiNAtion or Not With Paclitaxel as Second Line treatMent of esophagogastrIC Cancer

DYNAMIC
Start date: August 2019
Phase: Phase 2
Study type: Interventional

In this study, non-operable esophagogastric adenocarcinoma cancer patients or non-operable biliary cancer patients who's cancer progressed/spread/got worse after first line treatment will be treated with a novel combination of immunotherapy and/or chemotherapy. This study will take place in several countries across Europe. One hundred twenty-three (123) patients will be invited to participate in this study Biliary tract cancer (BTC), is a form of cancer that start in your bile ducts, a series of tubes that runs from the liver to the small intestines. It is not know yet the exact cause of BTC. For patients who have advanced or metastatic BTC (where surgery is not possible), chemotherapy is the first option for treatment. Chemotherapy with cisplatin and gemcitabine (CisGem) is the current standard of care. Esophageal cancer (EGC) is cancer that occurs in the esophagus, a long hollow tube that runs from your throat to your stomach. The accumulating abnormal cells form a tumor in the esophagus that can grow to invade nearby structures and spread to other parts of the body. It's thought that chronic irritation of your esophagus may contribute to the changes that cause esophageal cancer. The purpose of this study is to look at the risks and benefits of combining DKN-01 (humanized monoclonal antibody) and atezolizumab (immune therapy) with or without paclitaxel (chemotherapy). Immune therapy boosts the body's natural defenses to fight cancer. It uses specific products made either by participants' body or in a laboratory to improve, target or restore immune system function and control or stop cancer. Atezolizumab is such "immunotherapy" drug. DKN-01 is another new type of drug (humanized monoclonal antibody) in development as anticancer agent. Paclitaxel is a commonly-used chemotherapy drug of the class of taxanes used to treat a number of cancer types, it stimulates the cell to die or to stop the cell from dividing into two new cells.The idea behind combining these drugs is linked to targeting the immune system to attack the tumor. Combining immune and chemotherapy already demonstrated clinical activity in relapsed (return of the disease)/refractory (not responding to treatment) esophagogastric cancer patients.

NCT ID: NCT01180153 Not yet recruiting - Clinical trials for Biliary Tract Cancer

Study of S-1 Oxaliplatin (SOX) for Biliary Tract Cancer (BTC) (Ampullary Adenocarcinoma)

Start date: August 2010
Phase: Phase 2
Study type: Interventional

To evaluate efficacy and safety of S-1 Oxaliplatin (SOX) regimen to patients with unresectable, metastatic or locally advanced biliary tract or ampullary adenocarcinoma.